摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-氟-2-甲基喹啉 | 46001-36-9

中文名称
8-氟-2-甲基喹啉
中文别名
8-氟-2-甲基-喹啉
英文名称
8-fluoro-2-methylquinoline
英文别名
——
8-氟-2-甲基喹啉化学式
CAS
46001-36-9
化学式
C10H8FN
mdl
MFCD09744004
分子量
161.179
InChiKey
HJHYMLQMBHHNRJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933499090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    储存温度应保持在2-8℃,并确保环境干燥。

SDS

SDS:ed295552272738ae77a79637678bd21e
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 8-Fluoro-2-methylquinoline
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 8-Fluoro-2-methylquinoline
CAS number: 46001-36-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8FN
Molecular weight: 161.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    8-氟-2-甲基喹啉N-溴代丁二酰亚胺(NBS)偶氮二异丁腈 作用下, 以 various solvent(s) 为溶剂, 反应 5.0h, 生成 2-(溴甲基)-8-氟喹啉
    参考文献:
    名称:
    一种新颖,有效且结构简单的喹啉类LTD4拮抗剂的合成和SAR。
    摘要:
    CGP57698的琥珀酸部分中的两个双乙基(4- [3-(7-氟-2-喹啉基-甲氧基)苯基-氨基] -2,2-二乙基-4-氧代丁酸)负责这种喹啉型肽白三烯拮抗剂的体外和体内效力很高。描述了CGP57698及其类似物的合成与构效关系。
    DOI:
    10.1016/s0960-894x(98)00137-1
  • 作为产物:
    描述:
    以80%的产率得到8-氟-2-甲基喹啉
    参考文献:
    名称:
    High throughput one pot synthesis of 2-methylquinolines
    摘要:
    Various 2-methylquinolines have been successfully synthesized by using anilines and ethyl vinyl ether in 1:3 mole ratios in the presence of acetic acid. Stirring at rt for 3-4 h followed by reflux for 3.5-4 h resulted in the corresponding 2-methylquinolines in good yield. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2012.12.094
点击查看最新优质反应信息

文献信息

  • Synthesis of palladium complexes with quinolino-based tridentate ligands and their applications for norbornene polymerization
    作者:Haibin Yuan、Hui Liu、Fen You、Xiaochao Shi
    DOI:10.1016/j.inoche.2020.108139
    日期:2020.9
    Abstract Palladium complexes bearing new tridentate quinolino-based [N−NNox] ligands were synthesized and tested for the polymerization of norbornene. Upon activation of MAO, all the palladium complexes showed high catalytic activities for the vinyl-addition polymerization of norbornene up to 11.5 × 106 g of PNB (mol of Pd)−1h−1. The structure–activity relationships in the polymerization of norbornene
    摘要 合成了带有新型三齿喹啉基 [N-NNox] 配体配合物,并测试了降冰片烯的聚合反应。在 MAO 活化后,所有配合物都对降冰片烯乙烯基加成聚合显示出高催化活性,最高可达 11.5 × 106 g PNB(Pd 的摩尔数)-1h-1。仔细研究了降冰片烯聚合中的构效关系,即配体的空间和电效应。
  • IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER
    申请人:Connolly Peter J.
    公开号:US20150099730A1
    公开(公告)日:2015-04-09
    Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L 1 , a, b, m, n, R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein.
    公开了用于治疗多种疾病、综合征、状况和失调的化合物、组合物和方法,包括那些通过抑制脂肪酸合酶(FASN)酶介导的疾病,如癌症、肥胖或相关失调以及与肝脏相关的失调。这些化合物由公式(I)表示如下: 其中L1、a、b、m、n、R1、R2、R3、R4和R5在此定义。
  • [EN] QUINOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA<br/>[FR] DÉRIVÉS DE QUINOLINE ET APPLICATIONS ASSOCIÉES DANS LA RHINITE ET L'URTICAIRE
    申请人:GLAXO GROUP LTD
    公开号:WO2010094643A1
    公开(公告)日:2010-08-26
    The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.
    本发明涉及式(I)的化合物及其盐,其制备方法,含有它们的组合物,以及它们在治疗各种疾病(如过敏性鼻炎)中的用途。
  • [EN] AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS<br/>[FR] DERIVES AZABICYCLO (3.1.0) HEXANE UTILES COMME MODULATEURS DES RECEPTEURS D3 DE LA DOPAMINE
    申请人:GLAXO GROUP LTD
    公开号:WO2005080382A1
    公开(公告)日:2005-09-01
    The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.
    本发明涉及公式(I)的新化合物或其药学上可接受的盐,其中G选自以下组成的一组:苯基、吡啶基、苯并噻唑基、吲哚基;p是一个从0到5的整数;R1独立地选自以下组成的一组:卤素、羟基、基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4烷酰基;或对应于一个R5基团;R2是氢或C1-4烷基;R3是C1-4烷基;R4是氢,或苯基、杂环基、5-或6-成员杂芳基,或8-到11-成员双环基,其中任何一个基团可以选择地被来自以下组成的1、2、3或4个取代基所取代:卤素、基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基;R5是选自以下组成的基团:异噁唑基、-CH2-N-吡咯基、1,1-二氧化-2-异噻唑啉基、噻吩基、噻唑基、吡啶基、2-吡咯烷基,这样的基团可以选择地被一个或两个取代基所取代,所述取代基选自:卤素、基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基;当R1是且p为1时,该R1不位于与分子其余部分的连接键的邻位;当R1对应于R5时,p为1;它们的制备方法,用于这些方法的中间体,含有它们的药物组合物以及它们作为多巴胺D3受体调节剂在治疗中的用途,例如用于治疗药物依赖或作为抗精神病药物。
  • [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
    申请人:NURIX THERAPEUTICS INC
    公开号:WO2019148005A1
    公开(公告)日:2019-08-01
    Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.
    揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统,治疗适合免疫系统调节的疾病,并用于体内、体外或体外细胞的治疗。
查看更多